Discontinuation of prophylactic eculizumab therapy. Courses of prophylactic eculizumab therapies, according to the risk stratification and genetic background. Ecu, eculizumab; HR, high-risk; MR, moderate risk; MV, multiple complement variants; NV, no genetic variants.